166 related articles for article (PubMed ID: 12576419)
1. Flavopiridol-related proinflammatory syndrome is associated with induction of interleukin-6.
Messmann RA; Ullmann CD; Lahusen T; Kalehua A; Wasfy J; Melillo G; Ding I; Headlee D; Figg WD; Sausville EA; Senderowicz AM
Clin Cancer Res; 2003 Feb; 9(2):562-70. PubMed ID: 12576419
[TBL] [Abstract][Full Text] [Related]
2. Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea.
Innocenti F; Stadler WM; Iyer L; Ramírez J; Vokes EE; Ratain MJ
Clin Cancer Res; 2000 Sep; 6(9):3400-5. PubMed ID: 10999721
[TBL] [Abstract][Full Text] [Related]
3. Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms.
Senderowicz AM
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S61-73. PubMed ID: 12819936
[TBL] [Abstract][Full Text] [Related]
4. Relation of pro- and anti-inflammatory cytokines and the production of nitric oxide in patients receiving high-dose immunotherapy with interleukin-2.
Locker GJ; Kofler J; Stoiser B; Wilfing A; Wenzel C; Wögerbauer M; Steger GG; Zielinski CC; Mader R; Burgmann H
Eur Cytokine Netw; 2000 Sep; 11(3):391-6. PubMed ID: 11022123
[TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacology of flavopiridol following a 72-hour continuous infusion.
Rudek MA; Bauer KS; Lush RM; Stinson SF; Senderowicz AM; Headlee DJ; Arbuck SG; Cox MC; Murgo AJ; Sausville EA; Figg WD
Ann Pharmacother; 2003 Oct; 37(10):1369-74. PubMed ID: 14519054
[TBL] [Abstract][Full Text] [Related]
6. Phase I clinical and pharmacokinetic study of flavopiridol in children with refractory solid tumors: a Children's Oncology Group Study.
Whitlock JA; Krailo M; Reid JM; Ruben SL; Ames MM; Owen W; Reaman G;
J Clin Oncol; 2005 Dec; 23(36):9179-86. PubMed ID: 16361620
[TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias.
Karp JE; Passaniti A; Gojo I; Kaufmann S; Bible K; Garimella TS; Greer J; Briel J; Smith BD; Gore SD; Tidwell ML; Ross DD; Wright JJ; Colevas AD; Bauer KS
Clin Cancer Res; 2005 Dec; 11(23):8403-12. PubMed ID: 16322302
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.
Senderowicz AM; Headlee D; Stinson SF; Lush RM; Kalil N; Villalba L; Hill K; Steinberg SM; Figg WD; Tompkins A; Arbuck SG; Sausville EA
J Clin Oncol; 1998 Sep; 16(9):2986-99. PubMed ID: 9738567
[TBL] [Abstract][Full Text] [Related]
9. Systemic inflammatory response to exhaustive exercise. Cytokine kinetics.
Suzuki K; Nakaji S; Yamada M; Totsuka M; Sato K; Sugawara K
Exerc Immunol Rev; 2002; 8():6-48. PubMed ID: 12690937
[TBL] [Abstract][Full Text] [Related]
10. Role of the kidney in plasma cytokine removal in sepsis syndrome: a pilot study.
Graziani G; Bordone G; Bellato V; Finazzi S; Angelini C; Badalamenti S;
J Nephrol; 2006; 19(2):176-82. PubMed ID: 16736416
[TBL] [Abstract][Full Text] [Related]
11. Acute effect of hemodialysis on serum levels of the proinflammatory cytokines.
Tarakçioğlu M; Erbağci AB; Usalan C; Deveci R; Kocabaş R
Mediators Inflamm; 2003 Feb; 12(1):15-9. PubMed ID: 12745544
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer.
Tan AR; Yang X; Berman A; Zhai S; Sparreboom A; Parr AL; Chow C; Brahim JS; Steinberg SM; Figg WD; Swain SM
Clin Cancer Res; 2004 Aug; 10(15):5038-47. PubMed ID: 15297405
[TBL] [Abstract][Full Text] [Related]
13. Hypercytokinemia and hyperactivation of phospho-p38 mitogen-activated protein kinase in severe human influenza A virus infection.
Lee N; Wong CK; Chan PK; Lun SW; Lui G; Wong B; Hui DS; Lam CW; Cockram CS; Choi KW; Yeung AC; Tang JW; Sung JJ
Clin Infect Dis; 2007 Sep; 45(6):723-31. PubMed ID: 17712756
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial.
Théroux P; Armstrong PW; Mahaffey KW; Hochman JS; Malloy KJ; Rollins S; Nicolau JC; Lavoie J; Luong TM; Burchenal J; Granger CB
Eur Heart J; 2005 Oct; 26(19):1964-70. PubMed ID: 15872036
[TBL] [Abstract][Full Text] [Related]
15. Clinical trials referral resource. Clinical trials of flavopiridol.
Wright J; Blatner GL; Cheson BD
Oncology (Williston Park); 1998 Jul; 12(7):1018, 1023-4. PubMed ID: 9684276
[No Abstract] [Full Text] [Related]
16. A phase II study of flavopiridol in patients with advanced renal cell carcinoma: results of Southwest Oncology Group Trial 0109.
Van Veldhuizen PJ; Faulkner JR; Lara PN; Gumerlock PH; Goodwin JW; Dakhil SR; Gross HM; Flanigan RC; Crawford ED;
Cancer Chemother Pharmacol; 2005 Jul; 56(1):39-45. PubMed ID: 15791454
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia.
Frankel AE; Powell BL; Hall PD; Case LD; Kreitman RJ
Clin Cancer Res; 2002 May; 8(5):1004-13. PubMed ID: 12006512
[TBL] [Abstract][Full Text] [Related]
18. Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms.
Tan AR; Headlee D; Messmann R; Sausville EA; Arbuck SG; Murgo AJ; Melillo G; Zhai S; Figg WD; Swain SM; Senderowicz AM
J Clin Oncol; 2002 Oct; 20(19):4074-82. PubMed ID: 12351605
[TBL] [Abstract][Full Text] [Related]
19. Proinflammatory cytokine (IL-1beta, IL-6, IL-12, IL-18 and TNF-alpha) levels in sera of patients with subacute cutaneous lupus erythematosus (SCLE).
Maczynska I; Millo B; Ratajczak-Stefańska V; Maleszka R; Szych Z; Kurpisz M; Giedrys-Kalemba S
Immunol Lett; 2006 Jan; 102(1):79-82. PubMed ID: 16154204
[TBL] [Abstract][Full Text] [Related]
20. Functional improvement in heart failure patients treated with beta-blockers is associated with a decline of cytokine levels.
Mayer B; Holmer SR; Hengstenberg C; Lieb W; Pfeifer M; Schunkert H
Int J Cardiol; 2005 Aug; 103(2):182-6. PubMed ID: 16080978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
